Drugs that contain Selpercatinib

1. Drug name - RETEVMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(15 years from now)

US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(16 years from now)

CN110382494A LOXO ONCOLOGY INC Substituted Pyrazole And [1-A] Pyridine Compound As The Ret Kinase Inhibitor
Oct, 2037

(15 years from now)

CN110382494B LOXO ONCOLOGY INC Substituted Pyrazolo [1, 5-A] Pyridine Compound As Ret Kinase Inhibitor
Oct, 2037

(15 years from now)

EP3523301A1 LOXO ONCOLOGY INC Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
Oct, 2037

(15 years from now)

EP3523301B1 LOXO ONCOLOGY INC Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
Oct, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Oct, 2037

(15 years from now)

US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct, 2037

(15 years from now)

US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile Oct, 2038

(16 years from now)

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription
80MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.